BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Marianna Lakatos, Krisztina Hagymási, Gabriella Lengyel. Fatty liver and hepatitis C virus infectionOrvosi Hetilap 2011; 152(38): 1513 doi: 10.1556/OH.2011.29209
2
Jae Young Jang, Raymond T. Chung. New treatments for chronic hepatitis CThe Korean Journal of Hepatology 2010; 16(3): 263 doi: 10.3350/kjhep.2010.16.3.263
3
Mahmoud Aboelneen Khattab. Targeting host factors: A novel rationale for the management of hepatitis C virusWorld Journal of Gastroenterology 2009; 15(28): 3472-3479 doi: 10.3748/wjg.15.3472
4
Cristin Constantin Vere, Costin Teodor Streba, Liliana Streba, Ion Rogoveanu. Lipid Serum Profile in Patients with Viral Liver CirrhosisMedical Principles and Practice 2012; 21(6): 566 doi: 10.1159/000339206
5
Chia-Chi Wang, Pin-Nan Cheng, Jia-Horng Kao. Systematic review: chronic viral hepatitis and metabolic derangementAlimentary Pharmacology & Therapeutics 2019;  doi: 10.1111/apt.15575
6
Jacqueline G. O'Leary, Jessica L. Chan, Cory M. McMahon, Raymond T. Chung. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: A pilot clinical trialHepatology 2007; 45(4): 895 doi: 10.1002/hep.21554
7
Gabor Lendvai, Katalin Jármay, Gizella Karácsony, Tünde Halász, Ilona Kovalszky, Kornélia Baghy, Tibor Wittmann, Zsuzsa Schaff, András Kiss. Elevated miR-33a and miR-224 in steatotic chronic hepatitis C liver biopsiesWorld Journal of Gastroenterology 2014; 20(41): 15343-15350 doi: 10.3748/wjg.v20.i41.15343
8
Hung-Yu Sun, Pin-Nan Cheng, Chiung-Ying Tseng, Wei-Jen Tsai, Yen-Cheng Chiu, Kung-Chia Young. Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infectionGut 2018; 67(7): 1342 doi: 10.1136/gutjnl-2017-313832
9
J. H. Patel, J. F. L. Cobbold, H. C. Thomas, S. D. Taylor-Robinson. Hepatitis C and hepatic steatosisQJM 2010; 103(5): 293 doi: 10.1093/qjmed/hcp192
10
D. Ramcharran, A. S. Wahed, H. S. Conjeevaram, R. W. Evans, T. Wang, S. H. Belle, L. J. Yee. Serum lipids and their associations with viral levels and liver disease severity in a treatment-naïve chronic hepatitis C type 1-infected cohortJournal of Viral Hepatitis 2011; 18(4): e144 doi: 10.1111/j.1365-2893.2010.01394.x
11
Jian Yang, Hai-Qing Wang, Jia-Yin Yang, Tian-Fu Wen, Bo Li, Wen-Tao Wang, Lu-Nan Yan. Role of the postoperative cholesterol in early allograft dysfunction and survival after living donor liver transplantationHepatobiliary & Pancreatic Diseases International 2017; 16(6): 610 doi: 10.1016/S1499-3872(17)60008-0
12
Josephine H. Li, Xiang Qian Lao, Hans L. Tillmann, Jennifer Rowell, Keyur Patel, Alexander Thompson, Sunil Suchindran, Andrew J. Muir, John R. Guyton, Stephen D. Gardner, John G. McHutchison, Jeanette J. McCarthy. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infectionHepatology 2010; 51(6): 1904 doi: 10.1002/hep.23592
13
Naga Venkata Krishna Chand Pothineni, Robert Delongchamp, Srikanth Vallurupalli, Zufeng Ding, Yao Dai, Curt H. Hagedorn, Jawahar L. Mehta. Impact of Hepatitis C Seropositivity on the Risk of Coronary Heart Disease EventsThe American Journal of Cardiology 2014; 114(12): 1841 doi: 10.1016/j.amjcard.2014.09.020
14
Elemér Nemesánszky. Clinical consequences of chronic hepatitis C virus infection, diabetes mellitus and steatosis hepatitisOrvosi Hetilap 2011; 152(22): 882 doi: 10.1556/OH.2011.29107
15
Christian M. Lange, Michael von Wagner, Jörg Bojunga, Thomas Berg, Harald Farnik, Angela Hassler, Christoph Sarrazin, Eva Herrmann, Stefan Zeuzem. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirinEuropean Journal of Gastroenterology & Hepatology 2010; 22(11): 1303 doi: 10.1097/MEG.0b013e32833de92c
16
Ching-Sheng Hsu, Chun-Jen Liu, Chen-Hua Liu, Chi-Ling Chen, Ming-Yang Lai, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao. Metabolic profiles in patients with chronic hepatitis C: a case–control studyHepatology International 2008; 2(2): 250 doi: 10.1007/s12072-008-9064-3
17
Klara Werling, Zsuzsa Schaff, Elek Dinya, Zsolt Tulassay. Effect of Liver Steatosis on Therapeutic Response in Chronic Hepatitis C Virus Genotype 1 Infected Patients in HungaryPathology & Oncology Research 2010; 16(2): 149 doi: 10.1007/s12253-009-9195-4
18
Jacinta A Holmes, William Sievert, Alexander J Thompson. IL28Bpolymorphism and genetic biomarkers of viral clearance in hepatitis C virus infectionBiomarkers in Medicine 2011; 5(4): 461 doi: 10.2217/bmm.11.47
19
Mary A. Rodgers, Valerie A. Villareal, Esperance A. Schaefer, Lee F. Peng, Kathleen E. Corey, Raymond T. Chung, Priscilla L. Yang. Lipid Metabolite Profiling Identifies Desmosterol Metabolism as a New Antiviral Target for Hepatitis C VirusJournal of the American Chemical Society 2012; 134(16): 6896 doi: 10.1021/ja207391q
20
Ornit Chiba-Falek, Colton Linnertz, John Guyton, Stephen D. Gardner, Allen D. Roses, Jeanette J. McCarthy, Keyur Patel. Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infectionHuman Genetics 2012; 131(12): 1911 doi: 10.1007/s00439-012-1220-0